XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.45	-	-	-	-
Cost of Revenue	0.45	-	-	-	-
Gross Profit	0	-	-	-	-
Selling, General & Admin	2.08	0.73	0.85	1	0.91
Research & Development	0.1	0.03	0.03	0.03	0.04
Operating Expenses	2.18	0.77	0.88	1.03	0.95
Operating Income	-2.17	-0.77	-0.88	-1.03	-0.95
Interest Expense	-0.03	-	-	-	-
Interest & Investment Income	0.03	0.04	0.04	0.01	0.03
Currency Exchange Gain (Loss)	-0.03	-0.03	-0.02	0.01	0.01
Other Non Operating Income (Expenses)	-0.06	-0	-0.01	0.7	-2.19
EBT Excluding Unusual Items	-2.25	-0.76	-0.87	-0.31	-3.09
Gain (Loss) on Sale of Investments	1.09	-1.02	-0.48	0.75	0.14
Pretax Income	-1.16	-1.78	-1.35	0.44	-2.95
Income Tax Expense	-0.13	-	-	-	-
Earnings From Continuing Operations	-1.03	-1.78	-1.35	0.44	-2.95
Net Income	-1.03	-1.78	-1.35	0.44	-2.95
Net Income to Common	-1.03	-1.78	-1.35	0.44	-2.95
Shares Outstanding (Basic)	673	545	545	532	514
Shares Outstanding (Diluted)	704	545	545	616	514
Shares Change (YoY)	29.23%	-0.00%	-11.48%	19.71%	-
EPS (Basic)	-0.00	-0.00	-0.00	0.00	-0.01
EPS (Diluted)	-0.00	-0.00	-0.00	0.00	-0.01
Free Cash Flow	-1.67	-0.71	-0.9	-1.05	-0.85
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	-0.00
Gross Margin	0.66%	-	-	-	-
Operating Margin	-481.60%	-	-	-	-
Profit Margin	-227.72%	-	-	-	-
Free Cash Flow Margin	-370.73%	-	-	-	-
EBITDA	-1.97	-0.76	-0.88	-1.03	-0.95
D&A For EBITDA	0.2	0	0	0	0
EBIT	-2.17	-0.77	-0.88	-1.03	-0.95
Advertising Expenses	0.16	-	-	-	-

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q